MARKET

TARS

TARS

Tarsus Pharmaceuticals, Inc.
NASDAQ
73.83
+2.99
+4.22%
Closed 19:30 11/10 EST
OPEN
70.24
PREV CLOSE
70.84
HIGH
74.92
LOW
70.01
VOLUME
859.01K
TURNOVER
0
52 WEEK HIGH
91.53
52 WEEK LOW
53.89
MARKET CAP
3.64B
P/E (TTM)
-4.8628
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Veeva Systems (VEEV) and Vir Biotechnology (VIR)
TipRanks · 4h ago
Will Wider Q3 Loss Change Tarsus Pharmaceuticals Stock Narrative
Simply Wall St · 1d ago
Weekly Report: what happened at TARS last week (1102-1106)?
Weekly Report · 2d ago
What Is Drawing Fresh Attention To Tarsus Pharmaceuticals (TARS)?
Simply Wall St · 4d ago
Tarsus Pharmaceuticals price target raised to $102 from $94 at Mizuho
TipRanks · 5d ago
Tarsus Pharmaceuticals (TARS) Stock May Trade At A Discount On Strong Sales Growth
Simply Wall St · 5d ago
Tarsus Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones · 5d ago
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $97
Benzinga · 5d ago
More
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.

Webull offers Tarsus Pharmaceuticals Inc stock information, including NASDAQ: TARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARS stock methods without spending real money on the virtual paper trading platform.